VIDEO: Richard P. Baum, M.D., Ph.D., of the THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka in Germany, explains the research on the potential use of the radioisotope… view more
Credit: RP Baum, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany
RESTON, Va – German researchers have developed a novel diagnostic and therapeutic (theranostic) procedure for patients with ductal pancreatic adenocarcinoma, a deadly cancer with an extremely poor prognosis (five-year survival rate of less than 5 percent) and limited treatment options. The study is featured in the May issue of The Journal of Nuclear Medicine.
In early preclinical studies with animal models, the novel procedure significantly inhibited tumor growth. Focusing on the neurotensin receptor 1 (NTR1), a protein that is overexpressed in ductal pancreatic adenocarcinoma, researchers developed a DOTA-conjugated NTR1 antagonist 3BP-227 labeled with the radioisotope lutetium-177 (177Lu) to treat and monitor therapy.
For this study, 6 patients with confirmed metastatic ductal pancreatic adenocarcinoma, who had exhausted all other treatment options, received 177Lu-3BP-227 as salvage therapy. Scintigraphy and single-photon emission computed tomography was used with computed tomography (SPECT/CT) to determine the tumor uptake and the patients’ eligibility for treatment. If the patient’s
Article originally posted at